Print

BioProcessors Corp.’s SimCell(TM) Platform Selected By Novo Nordisk A/S (NVO) 
10/19/2005 5:12:11 PM

WOBURN, MA, U.S.A. September 13, 2005. BioProcessors announced the sale of the SimCell (TM) MicroBioreactor Automation Management System to Novo Nordisk A/S (NYSE: NVO), having successfully completed platform evaluation trials. The SimCell (TM) platform enables Novo Nordisk to rapidly accelerate their mammalian cell culture process development initiatives. As a result of the joint effort, the companies demonstrated the predictability and scalability of BioProcessors’ MicroBioreactor Array and a high-throughput robotic workstation to conventional bioreactor systems. BioProcessors’ SimCell MicroBioreactor solutions enable biotechnology and pharmaceutical companies to increase cell culture experiment capacity by orders-of-magnitude with greater data quality, faster cycles and lower costs than conventional biopharmaceutical processing methods.
//-->